Senior Vice President
Chief Operating Officer
Henric Bjarke joined Inozyme Pharma in July 2017 and serves as Senior Vice President and Chief Operating Officer. Mr. Bjarke brings a wealth of experience in metabolic and rare diseases to Inozyme Pharma, having previously served as Vice President and Therapeutic Area Head for the Metabolic Business Unit at Alexion Pharmaceuticals. In this role, he was responsible for the commercialization of asfotase alfa for the treatment hypophosphatasia, as well as other therapies.
Most recently, Mr. Bjarke was Chief Commercial Officer of Ophthotech, where he was responsible for building the U.S. commercial and operations infrastructure for Ophthotech’s product portfolio. Additionally, Mr. Bjarke has held multiple key supervisory roles with Pharmacia, Eyetech, and Watson Pharmaceuticals, where he managed multiple U.S. and global brands and successfully oversaw several major launches. Mr. Bjarke earned a B.A.Sc. in business administration and economics from Uppsala University, Sweden.